Quizartinib
CAS 950769-58-1 1 FDA-DMF supplierSmall Molecule
Overview
Quizartinib is a selective FLT3 inhibitor used in the treatment of acute myeloid leukemia (AML). It works by inhibiting the growth of cancer cells by targeting the receptor tyrosine kinase FLT3.
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Quizartinib expires 29 Sept 2033 and exclusivity 19 Jul 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.